Brokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Price Target at $10.80

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have been given an average rating of “Moderate Buy” by the six analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $10.80.

A number of research firms have weighed in on RGLS. StockNews.com raised Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a research note on Monday, November 11th.

Institutional Trading of Regulus Therapeutics

Hedge funds have recently bought and sold shares of the stock. Creative Planning bought a new position in shares of Regulus Therapeutics in the third quarter worth about $26,000. SG Americas Securities LLC purchased a new stake in Regulus Therapeutics in the 3rd quarter worth approximately $33,000. Jane Street Group LLC bought a new stake in Regulus Therapeutics during the 3rd quarter worth approximately $46,000. Barclays PLC lifted its holdings in Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock valued at $132,000 after purchasing an additional 62,549 shares in the last quarter. Finally, Rhumbline Advisers bought a new position in shares of Regulus Therapeutics in the second quarter worth approximately $136,000. Institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Stock Up 2.6 %

Shares of RGLS stock opened at $1.59 on Wednesday. The firm has a market capitalization of $104.15 million, a PE ratio of -1.49 and a beta of 1.61. The company has a 50 day moving average price of $1.53 and a 200-day moving average price of $1.68. Regulus Therapeutics has a 52 week low of $1.08 and a 52 week high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Analysts anticipate that Regulus Therapeutics will post -0.88 earnings per share for the current year.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.